Please login to the form below

Not currently logged in
Email:
Password:

Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

She arrives from US-based Dimension Therapeutics, where she was CEO

Annalisa JenkinsUK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018 launch of the biomarker-based liquid biopsy system (LBS).

Dr Jenkins joins the company from Dimension Therapeutics, where she served as its chief executive officer, and her previous roles have seen her gain expertise in scientific research, clinical development, regulatory process and commercialisation.

Jon Moynihan, chairman of PlaqueTec, said: “Dr Jenkins is a passionate and energetic leader with a proven track record of successfully translating exciting science from bench to bedside.

“We are pleased to welcome her to PlaqueTec at an important time for the company, as we will surely benefit from her extensive expertise in growing both private and public companies in the life sciences industry.”

Prior to Dimension Therapeutics, Dr Jenskins served as executive vice president, head of global research and development for Merck Serono and she has also had a nearly 15-year career at Bristol-Myers Squibb.

She said: “I look forward to working with the highly accomplished leadership team and board of directors at PlaqueTec to help advance the study and launch of its pioneering system through increased academic and biopharma collaborations.”

22nd November 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....